Investors interested in medical drug stocks have probably come across both Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
At Zacks, we concentrate on the reliable Zacks Rank system, which highlights earnings estimates and changes in those estimates to identify excellent stocks. At the same time, we keep an eye on the most recent trends in value, growth, and momentum to support our top selections.
Takeda Pharmaceutical provides appealing dividends and has a low price/book ratio, which makes it attractive even with recent price declines and uncertainties in US policies. The company shared strong earnings for Q3, increased its full-year FY2025 forecast, and introduced a new CEO along with a major share buyback plan. Revenue and operating income were better than expected, thanks to a shortage of generic Vyvanse, favorable currency exchange rates, and lower amortization of intangible assets.
Takeda Pharmaceutical Company Limited (NYSE:TAK) will hold its Q3 2025 Results Conference Call on January 30, 2025, at 5:30 AM ET. Key participants from the company include Christopher O'Reilly, Christophe Weber, Milano Furuta, and Andy Plump. During the call, Christopher O'Reilly will remind everyone that they will be discussing forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995.
On Thursday, Takeda Pharmaceutical, Japan's largest drug company, announced its third-quarter profits, which were lower than what analysts had expected. This comes as the company is still working on its restructuring efforts.
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) has released its earnings results for the third quarter of fiscal year 2024, covering the nine months up to December 31, 2024. The company reported a significant growth of 14.6% in its Growth & Launch Products. Takeda has also improved its full-year growth forecast due to strong product performance, operational efficiencies, and updated foreign exchange expectations.
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) has announced that the Japanese Ministry of Health, Labour and Welfare has approved HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for patients with agammaglobulinemia or hypogammaglobulinemia. These conditions are marked by very low or absent antibody levels, leading to a higher risk of serious infections due to primary or secondary immunodeficiency.
Takeda Pharmaceutical provides a strong dividend yield, but its reliability is uncertain because of exchange rate risks and a payout ratio that frequently goes over 100%. Although there is growth in areas like Livtencity and Qdenga, the company's high debt and weak currency make it a risky choice for dividend investors. The drop in the yen's value compared to the dollar greatly affects revenue growth and the stability of dividends for investors in the U.S.
Alloy Therapeutics Inc. has announced a partnership and licensing deal with Takeda Pharmaceutical Company to advance Takeda's unique CAR-T and CAR-NK cell platforms derived from induced pluripotent stem cells. Alloy aims to speed up the development of these innovative technologies. This collaboration highlights Alloy's commitment to making advanced drug discovery tools more accessible.
Masa Takeda, a portfolio manager at Hennessy Japan Fund, appears on CNBC's 'Power Lunch' to share his positive outlook on Japan. He also talks about the potential impact of president-elect Trump's suggested tariffs on Japanese businesses and other related topics.